Study long-term safety of stem cell injections for retinal disease
Treatments studied
Part of Eyes & vision, Genetic & congenital clinical trials.
This trial checks whether a stem cell treatment is safe over the long term for people with retinitis pigmentosa. You would get an injection near the eye and then do several follow-up eye tests and quality-of-life surveys to monitor effects.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have retinitis pigmentosa with visual field loss between 25% and 50% on a standard vision field test (Humphrey perimetry)
- You agree to sign informed consent
- You agree to receive an injection near the eye using stem cells made from umbilical cord tissue
- You are willing to return for scheduled follow-up visits and multiple eye tests (visual field, Snellen vision, OCT scan, electroretinogram, and a quality-of-life questionnaire)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether stem cell–based injections near the eye can slow vision loss in people with retinitis pigmentosa. It compares stem cells made from umbilical cord tissue and asks participants to complete several eye tests over time to measure vision changes.
This trial tests whether tiny particles from stem cells, called extracellular vesicles, can help people with retinitis pigmentosa. It aims to see if these particles are safe and can improve vision.
This study looks at stem-cell treatment to help vision in adults whose retina or optic nerve damage is not expected to improve on its own. You may be a candidate if your eye exam shows documented, stable or slowly changing damage and you can safely complete follow-up eye visits.
This trial tests a new medicine, DSP-3077, given as a single injection into one eye to see if it is safe for people with retinitis pigmentosa. It is for adults with advanced vision loss who have no other major eye diseases.
This trial tests an experimental drug called IGT001 for people with retinitis pigmentosa, a genetic eye disease that causes vision loss. The goal is to see if it is safe and can help slow or improve vision.
This program tests an experimental gene therapy for adults with retinitis pigmentosa (RP), an inherited eye disease that causes vision loss. It aims to see if the treatment can help preserve or improve vision.
Hear when a new Retinitis Pigmentosa trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.